AbbVie Inc (ABBV)
Pretax margin
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Earnings before tax but after interest (EBT) | US$ in thousands | 3,716,000 | 6,250,000 | 13,477,000 | 12,989,000 | 3,398,000 |
| Revenue | US$ in thousands | 56,334,000 | 54,318,000 | 58,054,000 | 56,197,000 | 45,804,000 |
| Pretax margin | 6.60% | 11.51% | 23.21% | 23.11% | 7.42% |
December 31, 2024 calculation
Pretax margin = EBT ÷ Revenue
= $3,716,000K ÷ $56,334,000K
= 6.60%
The pretax margin for AbbVie Inc has shown significant fluctuations over the years based on the provided data:
- In 2020, the pretax margin was 7.42%, indicating that for every dollar of revenue generated, AbbVie Inc retained $0.0742 before accounting for taxes and other expenses.
- The pretax margin saw a substantial increase in 2021, reaching 23.11%, signifying improved operational efficiency and profitability during that period.
- This positive trend continued into 2022, with the pretax margin slightly increasing to 23.21%, reflecting continued strong performance.
- However, in 2023, there was a notable decline in the pretax margin to 11.51%, which suggests potential challenges or increased costs impacting profitability.
- The downward trend persisted into 2024, with the pretax margin falling to 6.60%, indicating a significant decrease in profitability compared to the previous year.
Overall, the analysis of AbbVie Inc's pretax margin reveals varying levels of profitability over the years, with notable fluctuations that may warrant further investigation into the factors influencing the company's financial performance.
Peer comparison
Dec 31, 2024